Group 2 innate lymphocytes at the interface between innate and adaptive immunity

Annals of the New York Academy of Sciences

Volumn 1417, Issue 1, 2016, Pages 87-103

  Schuijs, Martijn J ^a   Halim, Timotheus Y F ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

ILC2; Innate lymphoid cells; T helper cells; TH2; Type 2 response

Indexed keywords

CYTOKINE; HORMONE; INTERLEUKIN 33; LIPID; THYMIC STROMAL LYMPHOPOIETIN;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; CELL INTERACTION; CELL SURFACE; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LIGAND BINDING; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOID CELL; NERVE CELL; NONHUMAN; RECEPTOR BINDING; REVIEW; SKIN;

EID: 85057363502     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13604     Document Type: Review

References (185)

1. Moro, K. et al. 2010. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463: 540–544.
2. Neill, D.R. et al. 2010. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367–1370.
3. Price, A.E. et al. 2010. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl. Acad. Sci. USA 107: 11489–11494.
4. Tait, W.E.D. & D. Artis. 2016. Emerging concepts and future challenges in innate lymphoid cell biology. J. Exp. Med. 213: 2229–2248.
5. McKenzie, A.N., H. Spits, & G. Eberl. 2014. Innate lymphoid cells in inflammation and immunity. Immunity 41: 366–374.
6. Artis, D. & H. Spits. 2015. The biology of innate lymphoid cells. Nature 517: 293–301.
7. Halim, T.Y. 2016. Group 2 innate lymphoid cells in disease. Int. Immunol. 28: 13–22.
8. Zook, E.C. & B.L. Kee. 2016. Development of innate lymphoid cells. Nat. Immunol. 17: 775–782.
9. Shih, H.-Y. et al. 2016. Developmental acquisition of reg-ulomes underlies innate lymphoid cell functionality. Cell 165: 1120–1133.
10. Vivier, E. et al. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44–49.
11. Schuster, I.S., J.D. Coudert, C.E. Andoniou, & M.A. Degli-Esposti. 2016. “Natural Regulators”: NK cells as modulators of T cell immunity. Front. Immunol. 7: 235.
12. Withers, D.R. 2016. Innate lymphoid cell regulation of adaptive immunity. Immunology 149: 123–130.
13. Fort, M.M. et al. 2001. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15: 985–995.
14. Fallon, P.G. et al. 2006. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203: 1105–1116.
15. Kondo, Y. et al. 2008. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20: 791–800.
16. Gasteiger, G., X. Fan, S. Dikiy, et al. 2015. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350: 981–985.
17. Moro, K. et al. 2016. Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17: 76–86.
18. Lim, A.I., T. Verrier, C.A. Vosshenrich, et al. 2017. Developmental options and functional plasticity of innate lymphoid cells. Curr. Opin. Immunol. 44: 61–68.
19. Seillet, C. et al. 2016. Deciphering the innate lymphoid cell transcriptional program. Cell Rep. 17: 436– 447.
20. Yang, Q. et al. 2015. TCF-1 upregulation identifies early innate lymphoid progenitors in the bone marrow. Nat. Immunol. 16: 1044–1050.
21. Constantinides, M.G., B.D. McDonald, P.A. Verhoef, & A. Bendelac. 2014. A committed precursor to innate lymphoid cells. Nature 508: 397–401.
22. Seehus, C.R. et al. 2015. The development of innate lymphoid cells requires TOX-dependent generation of a common innate lymphoid cell progenitor. Nat. Immunol. 16: 599–608.
23. Klose, C.S.N. et al. 2014. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157: 340–356.
24. Verhoef, P.A. et al. 2016. Intrinsic functional defects of type 2 innate lymphoid cells impair innate allergic inflammation in promyelocytic leukemia zinc finger (PLZF)–deficient mice. J. Allergy Clin. Immunol. 137: 591–600.e1.
25. Scoville, S.D. et al. 2016. A progenitor cell expressing transcription factor RORγt generates all human innate lymphoid cell subsets. Immunity 44: 1140–1150.
26. Hoyler, T. et al. 2012. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37: 634–648.
27. Mjosberg, J. et al. 2012. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37: 649–659.
28. Wong, S.H. et al. 2012. Transcription factor RORα is critical for nuocyte development. Nat. Immunol. 13: 229–236.
29. Halim, T.Y. et al. 2012. Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. Immunity 37: 463–474.
30. Spooner, C.J. et al. 2013. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat. Immunol. 14: 1229–1236.
31. Yang, Q. et al. 2013. T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity 38: 694–704.
32. + innate lymphocyte differentiation and protection in intestinal inflammation. J. Immunol. 191: 4383–4391.
33. Zook, E.C. et al. 2016. The ETS1 transcription factor is required for the development and cytokine-induced expansion of ILC2. J. Exp. Med. 213: 687–696.
34. Walker, J.A. et al. 2015. Bcl11b is essential for group 2 innate lymphoid cell development. J. Exp. Med. 212: 875–882.
35. Tindemans, I., N. Serafini, J.P. Di Santo, & R.W. Hendriks. 2014. GATA-3 function in innate and adaptive immunity. Immunity 41: 191–206.
36. Yagi, R. et al. 2014. The transcription factor GATA3 is critical for the development of all IL-7Rα-expressing innate lymphoid cells. Immunity 40: 378–388.
37. + group 3 innate lymphoid cells. J. Exp. Med. 211: 199–208.
38. Amsen, D. et al. 2007. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 27: 89–99.
39. Mjosberg, J.M. et al. 2011. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12: 1055– 1062.
40. Andrew, N.J.M. 2014. Type-2 innate lymphoid cells in asthma and allergy. Ann. Am. Thorac. Soc. 11: S263–S270.
41. Spits, H. et al. 2013. Innate lymphoid cells—a proposal for uniform nomenclature. Nat. Rev. Immunol. 13: 145– 149.
42. Antignano, F. et al. 2016. G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program. J. Exp. Med. 213: 1153– 1162.
43. Johansson, K., C. Malmhäll, P. Ramos-Ramírez, & M. Rådinger. 2017. MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation. J. Allergy Clin. Immunol. 139: 1007–1016.e9.
44. Singh, P.B. et al. 2017. MicroRNA regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation. J. Exp. Med. 214: 3627–3643.
45. Van Dyken, S.J. et al. 2016. A tissue checkpoint regulates type 2 immunity. Nat. Immunol. 17: 1381–1387.
46. Kim, B.S. & D. Artis. 2015. Group 2 innate lymphoid cells in health and disease. Cold Spring Harb. Perspect. Biol. 7. https://doi.org/10.1101/cshperspect.a016337.
47. Hammad, H. & B.N. Lambrecht. 2015. Barrier epithelial cells and the control of type 2 immunity. Immunity 43: 29–40.
48. Huang, Y. et al. 2015. IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential ‘inflammatory’ type 2 innate lymphoid cells. Nat. Immunol. 16: 161–169.
49. Barlow, J.L. et al. 2013. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132: 933–941.
50. Gronke, K. & A. Diefenbach. 2016. Tuft cell-derived IL-25 activates and maintains ILC2. Immunol. Cell Biol. 94: 221–223.
51. Bando, J.K. & M. Colonna. 2016. Innate lymphoid cell function in the context of adaptive immunity. Nat. Immunol. 17: 783–789.
52. von Moltke, J., M. Ji, H.-E. Liang, & R.M. Locksley. 2016. Tuft-cell-derived IL-25 regulates an intestinal ILC2– epithelial response circuit. Nature 529: 221–225.
53. Gerbe, F. et al. 2016. Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites. Nature 529: 226–230.
54. Howitt, M.R. et al. 2016. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. Science 351: 1329–1333.
55. Van Dyken, S.J. et al. 2014. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and γδ T cells. Immunity 40: 414– 424.
56. Ealey, K.N., K. Moro, & S. Koyasu. 2017. Are ILC2s Jekyll and Hyde in airway inflammation? Immunol. Rev. 278: 207– 218.
57. Cayrol, C. & J.-P. Girard. 2014. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31: 31–37.
58. Luthi, A.U. et al. 2009. Suppression of interleukin-33 bioac-tivity through proteolysis by apoptotic caspases. Immunity 31: 84–98.
59. Gordon, E.D. et al. 2016. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc. Natl. Acad. Sci. USA 113: 8765–8770.
60. Lott, J.M., T.L. Sumpter, & H.R. Turnquist. 2015. New dog and new tricks: evolving roles for IL-33 in type 2 immunity. J. Leukoc. Biol. 97: 1037–1048.
61. Yasuda, K. et al. 2012. Contribution of IL-33–activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc. Natl. Acad. Sci. USA 109: 3451–3456.
62. Hardman, C.S., V. Panova, & A.N. McKenzie. 2013. IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur. J. Immunol. 43: 488–498.
63. Liew, F.Y., J.-P. Girard, & H.R. Turnquist. 2016. Interleukin-33 in health and disease. Nat. Rev. Immunol. 16: 676–689.
64. Halim, T.Y., R.H. Krauss, A.C. Sun, & F. Takei. 2012. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36: 451–463.
65. Halim, T. et al. 2014. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40: 425–435.
66. Li, B.W.S. et al. 2016. T cells are necessary for ILC2 activation in house dust mite-induced allergic airway inflammation in mice. Eur. J. Immunol. 46: 1392–1403.
67. Furusawa, J.-I. et al. 2013. Critical role of p38 and GATA3 in natural helper cell function. J. Immunol. 191: 1818–1826.
68. de Kleer, I.M. et al. 2016. Perinatal activation of the interleukin-33 pathway promotes type 2 immunity in the developing lung. Immunity 45: 1285–1298.
69. Bouchery, T. et al. 2015. ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. Nat. Commun. 6: 6970.
70. Bal, S.M. et al. 2016. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat. Immunol. 17: 636–645.
71. Ohne, Y. et al. 2016. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat. Immunol. 17: 646–655.
72. Shimokawa, C. et al. 2017. Mast cells are crucial for induction of group 2 innate lymphoid cells and clearance of helminth infections. Immunity 46: 863–874.e4.
73. Tait, W.E.D. et al. 2015. The prostaglandin D receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol. 8: 1313– 1323.
74. Suzuki, M., R. Morita, Y. Hirata, et al. 2015. Spred1, a suppressor of the Ras–ERK pathway, negatively regulates expansion and function of group 2 innate lymphoid cells. J. Immunol. 195: 1273–1281.
75. Mohapatra, A. et al. 2016. Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol. 9: 275–286.
76. Wilhelm, C. et al. 2011. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat. Immunol. 12: 1071–1077.
77. Turner, J.E. et al. 2013. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J. Exp. Med. 210: 2951–2965.
78. Tsilingiri, K., G. Fornasa & M. Rescigno. 2017. Thymic stromal lymphopoietin: to cut a long story short. Cell. Mol. Gastroenterol. Hepatol. 3: 174–182.
79. Haber, A.L. et al. 2017. A single-cell survey of the small intestinal epithelium. Nature 551: 333–339.
80. Ziegler, S.F. & D. Artis. 2010. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11: 289– 293.
81. Kim, B.S. et al. 2013. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 5: 170ra116.
82. Kabata, H. et al. 2013. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat. Commun. 4: 2675.
83. Liu, S. et al. 2018. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. J. Allergy Clin. Immunol. 141: 257–268.e6.
84. Gauvreau, G.M. et al. 2014. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370: 2102–2110.
85. Roediger, B. et al. 2015. IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation. J. Allergy Clin. Immunol. 136: 1653–1663.e7.
86. + T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41: 283–295.
87. Nussbaum, J.C. et al. 2013. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502: 245– 248.
88. Ghaedi, M. et al. 2016. Common-lymphoid-progenitor-independent pathways of innate and T lymphocyte development. Cell Rep. 15: 471–480.
89. Motomura, Y. et al. 2014. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40: 758–771.
90. Vely, F. et al. 2016. Evidence of innate lymphoid cell redundancy in humans. Nat. Immunol. 17: 1291–1299.
91. Molofsky, A.B. et al. 2015. Interleukin-33 and interferon-γ counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43: 161–174.
92. Duerr, C.U. et al. 2015. Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat. Immunol. 17: 65.
93. Califano, D. et al. 2018. IFN-γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. Mucosal Immunol. 11: 209–219.
94. Stier, M.T. et al. 2017. STAT1 represses cytokine-producing group 2 and group 3 innate lymphoid cells during viral infection. J. Immunol. 199: 510–519.
95. Lim, A.I. et al. 2016. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213: 569–583.
96. Silver, J.S. et al. 2016. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat. Immunol. 17: 626– 635.
97. Meylan, F. et al. 2014. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 7: 958–968.
98. Yu, X. et al. 2014. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol. 7: 730–740.
99. Salimi, M. et al. 2016. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J. Immunol. 196: 45–54.
100. Maazi, H. et al. 2015. ICOS:ICOS–ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity 42: 538–551.
101. Paclik, D., C. Stehle, A. Lahmann, et al. 2015. ICOS regulates the pool of group 2 innate lymphoid cells under homeostatic and inflammatory conditions in mice. Eur. J. Immunol. 45: 2766–2772.
102. Salimi, M. et al. 2013. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210: 2939–2950.
103. Hannun, Y.A. & L.M. Obeid. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9: 139–150.
104. Doherty, T.A. et al. 2013. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J. Allergy Clin. Immunol. 132: 205–213.
105. Lund, S.J. et al. 2017. Leukotriene C4 potentiates IL-33– induced group 2 innate lymphoid cell activation and lung inflammation. J. Immunol. 199: 1096–1104.
106. Barnig, C. et al. 2013. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5: 174ra126.
107. Xue, L. et al. 2014. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 133: 1184–1194.
108. Takahashi, Y. et al. 2002. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 137: 315–322.
109. Weisong, Z. et al. 2016. Prostaglandin I2 signaling and inhibition of group 2 innate lymphoid cell responses. Am. J. Respir. Crit. Care Med. 193: 31–42.
110. von Moltke, J. et al. 2017. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. J. Exp. Med. 214: 27–37.
111. Cardoso, V. et al. 2017. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature 549: 277–281.
112. Robinette, M.L. et al. 2015. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16: 306–317.
113. Laffont, S. et al. 2017. Androgen signaling negatively controls group 2 innate lymphoid cells. J. Exp. Med. 214: 1581– 1592.
114. Carey, M.A. et al. 2007. The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L272– L278.
115. Csóka, B. et al. 2017. Adenosine receptors differentially regulate type 2 cytokine production by IL-33–activated bone marrow cells, ILC2s, and macrophages. FASEB J. https://doi.org/10.1096/fj.201700770R.
116. Klose, C.S.N. et al. 2017. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature 549: 282–286.
117. Ibiza, S. et al. 2016. Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. Nature 535: 440–443.
118. Wallrapp, A. et al. 2017. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation. Nature 549: 351– 356.
119. Brestoff, J.R. et al. 2015. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519: 242–246.
120. Pelly, V.S. et al. 2016. IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol. 9: 1407–1417.
121. Noval, R.M., O.T. Burton, H.C. Oettgen, & T. Chatila. 2016. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J. Allergy Clin. Immunol. 138: 801–811.e9.
122. Wynn, T.A. 2015. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15: 271–282.
123. Rauber, S. et al. 2017. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 23: 938–944.
124. Smith, K.A. et al. 2016. Low-level regulatory T-cell activity is essential for functional type-2 effector immunity to expel gastrointestinal helminths. Mucosal Immunol. 9: 428– 443.
125. Wang, S. et al. 2017. Regulatory innate lymphoid cells control innate intestinal inflammation. Cell 171: 201–216.e18.
126. Seehus, C.R. et al. 2017. Alternative activation generates IL-10 producing type 2 innate lymphoid cells. Nat. Commun. 8: 1900.
127. Monticelli, L.A. et al. 2011. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12: 1045–1054.
128. + T cells cooperate to mediate type 2 immune response in mice. Allergy 69: 1300–1307.
129. Michael, C. 2010. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28: 57–78.
130. Webb, G.J., G.M. Hirschfield, & P.J.L. Lane. 2016. OX40, OX40L and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 50: 312–332.
131. Yu, Y. et al. 2016. Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway. Nature 539: 102–106.
132. Schwartz, C. et al. 2017. ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. J. Exp. Med. 214: 2507–2521.
133. Molofsky, A.B. et al. 2013. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210: 535–549.
134. Nguyen, K.D. et al. 2011. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480: 104–108.
135. Qiu, Y. et al. 2014. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157: 1292–1308.
136. Fischer, K. et al. 2017. Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat. Med. 23: 623.
137. Lee, M.W. et al. 2015. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160: 74–87.
138. Flach, M. & A. Diefenbach. 2015. Adipose tissue: ILC2 crank up the heat. Cell Metab. 21: 152–153.
139. Spencer, S.P. et al. 2014. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 343: 432–437.
140. Lambrecht, B.N. & H. Hammad. 2015. The immunology of asthma. Nat. Immunol. 16: 45–56.
141. Moffatt, M.F. et al. 2010. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363: 1211–1221.
142. Gold, M.J. et al. 2014. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. J. Allergy Clin. Immunol. 133: 1142– 1148.
143. De Grove, K.C. et al. 2017. Dysregulation of type 2 innate lymphoid cells and TH2 cells impairs pollutant-induced allergic airway responses. J. Allergy Clin. Immunol. 139: 246–257.e4.
144. Klein, W.R.G. et al. 2012. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur. J. Immunol. 42: 1106– 1116.
145. Snelgrove, R.J. et al. 2014. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J. Allergy Clin. Immunol. 134: 583–592.e6.
146. Martinez-Gonzalez, I. et al. 2016. Allergen-experienced group 2 innate lymphoid cells acquire memory-like properties and enhance allergic lung inflammation. Immunity 45: 198–208.
147. + CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188: 1503–1513.
148. Salmond, R.J. et al. 2012. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J. Allergy Clin. Immunol. 130: 1159–1166.e6.
149. Hung, L.Y. et al. 2013. IL-33 drives biphasic IL-13 production for noncanonical type 2 immunity against hookworms. Proc. Natl. Acad. Sci. USA 110: 282–287.
150. Guo, L. et al. 2015. Innate immunological function of TH2 cells in vivo. Nat. Immunol. 16: 1051–1059.
151. + Th2 cell responses. J. Immunol. 192: 2442– 2448.
152. von Burg, N., G. Turchinovich, & D. Finke. 2015. Maintenance of immune homeostasis through ILC/T cell interactions. Front. Immunol. 6: 416.
153. Halim, T.Y.F. et al. 2016. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat. Immunol. 17: 57–64.
154. Rigas, D. et al. 2017. Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction. J. Allergy Clin. Immunol. 139: 1468–1477.e2.
155. Sugita, K. et al. 2018. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J. Allergy Clin. Immunol. 141: 300–310.e11.
156. Steer, C.A. et al. 2017. Group 2 innate lymphoid cell activation in the neonatal lung drives type 2 immunity and allergen sensitization. J. Allergy Clin. Immunol. 140: 593– 595.e3.
157. Saluzzo, S. et al. 2017. First-breath-induced type 2 pathways shape the lung immune environment. Cell Rep. 18: 1893– 1905.
158. Monticelli, L.A. et al. 2016. Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nat. Immunol. 17: 656–665.
159. Smith, S.G. et al. 2016. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137: 75–86.e8.
160. Maggi, L. et al. 2017. Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production. J. Allergy Clin. Immunol. 139: 964–976.e4.
161. Lombardi, V. et al. 2016. Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects. J. Allergy Clin. Immunol. 138: 305–308.
162. + type 2 innate lymphoid cells correlate with asthma control status and treatment response. Am. J. Respir. Cell Mol. Biol. 55: 675–683.
163. Ruchong, C. et al. 2017. Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma. Am. J. Respir. Crit. Care Med. 196: 700–712.
164. Gonem, S. et al. 2016. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir. Med. 4: 699–707.
165. Chang, Y.J. et al. 2011. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12: 631–638.
166. Hong, J.Y. et al. 2014. Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells. J. Allergy Clin. Immunol. 134: 429–439.
167. Beale, J. et al. 2014. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med. 6: 256ra134.
168. Shim, D.H. et al. 2015. Pandemic influenza virus, pH1N1, induces asthmatic symptoms via activation of innate lymphoid cells. Pediatr. Allergy Immunol. 26: 780– 788.
169. Han, M. et al. 2017. IFN-γ blocks development of an asthma phenotype in rhinovirus-infected baby mice by inhibiting type 2 innate lymphoid cells. Am. J. Respir. Cell Mol. Biol. 56: 242–251.
170. Stier, M.T. et al. 2016. Respiratory syncytial virus infection activates IL-13–producing group 2 innate lymphoid cells through thymic stromal lymphopoietin. J. Allergy Clin. Immunol. 138: 814–824.e11.
171. Saravia, J. et al. 2015. Respiratory syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog. 11: e1005217.
172. Leung, D.Y.M., M. Boguniewicz, M.D. Howell, et al. 2004. New insights into atopic dermatitis. J. Clin. Invest. 113: 651–657.
173. Bin, L. & D.Y.M. Leung. 2016. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin. Immunol. 12: 52.
174. Roediger, B. et al. 2013. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol. 14: 564–573.
175. Imai, Y. et al. 2013. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. USA 110: 13921–13926.
176. Rak, G.D. et al. 2016. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Invest. Dermatol. 136: 487–496.
177. Mashiko, S., H. Mehta, R. Bissonnette, & M. Sarfati. 2017. Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis. J. Dermatol. Sci. 88: 167–174.
178. Henderson, J. et al. 2008. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J. Allergy Clin. Immunol. 121: 872–877 e879.
179. Irvine, A.D., W.H. McLean, & D.Y. Leung. 2011. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365: 1315–1327.
180. McHedlidze, T. et al. 2013. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39: 357–371.
181. Heymann, F. & F. Tacke. 2016. Immunology in the liver— from homeostasis to disease. Nat. Rev. Gastroenterol. Hepatol. 13: 88–110.
182. Liang, Y. et al. 2013. IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J. Immunol. 190: 5666– 5675.
183. Gadani, S.P., I. Smirnov, A.T. Smith, et al. 2017. Characterization of meningeal type 2 innate lymphocytes and their response to CNS injury. J. Exp. Med. 214: 285–296.
184. Besnard, A.G. et al. 2015. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog. 11: e1004607.
185. Jiang, H.R. et al. 2012. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur. J. Immunol. 42: 1804– 1814.